These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 8875087)

  • 1. Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM.
    Torlone E; Pampanelli S; Lalli C; Del Sindaco P; Di Vincenzo A; Rambotti AM; Modarelli F; Epifano L; Kassi G; Perriello G; Brunetti P; Bolli G
    Diabetes Care; 1996 Sep; 19(9):945-52. PubMed ID: 8875087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
    Ahmed AB; Mallias J; Home PD
    Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients. A comparison with human regular insulin during a three-meal test period.
    Jacobs MA; Keulen ET; Kanc K; Casteleijn S; Scheffer P; Devillé W; Heine RJ
    Diabetes Care; 1997 Aug; 20(8):1279-86. PubMed ID: 9250454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.
    Lalli C; Ciofetta M; Del Sindaco P; Torlone E; Pampanelli S; Compagnucci P; Cartechini MG; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1999 Mar; 22(3):468-77. PubMed ID: 10097931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime.
    Ciofetta M; Lalli C; Del Sindaco P; Torlone E; Pampanelli S; Mauro L; Chiara DL; Brunetti P; Bolli GB
    Diabetes Care; 1999 May; 22(5):795-800. PubMed ID: 10332684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin.
    Joseph SE; Korzon-Burakowska A; Woodworth JR; Evans M; Hopkins D; Janes JM; Amiel SA
    Diabetes Care; 1998 Dec; 21(12):2098-102. PubMed ID: 9839100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM.
    Torlone E; Fanelli C; Rambotti AM; Kassi G; Modarelli F; Di Vincenzo A; Epifano L; Ciofetta M; Pampanelli S; Brunetti P
    Diabetologia; 1994 Jul; 37(7):713-20. PubMed ID: 7958544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight.
    Mohn A; Matyka KA; Harris DA; Ross KM; Edge JA; Dunger DB
    Diabetes Care; 1999 Jan; 22(1):27-32. PubMed ID: 10333899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of Lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses ghrelin, compared with regular/NPH insulin in female patients with type 1 diabetes.
    Griffen SC; Oostema K; Stanhope KL; Graham J; Styne DM; Glaser N; Cummings DE; Connors MH; Havel PJ
    J Clin Endocrinol Metab; 2006 Feb; 91(2):485-91. PubMed ID: 16317063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin lispro in CSII: results of a double-blind crossover study.
    Zinman B; Tildesley H; Chiasson JL; Tsui E; Strack T
    Diabetes; 1997 Mar; 46(3):440-3. PubMed ID: 9032100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Counterregulatory hormone responses and symptoms during hypoglycaemia induced by porcine, human regular insulin, and Lys(B28), Pro(B29) human insulin analogue (insulin Lispro) in healthy male volunteers.
    Jacobs MA; Salobir B; Popp-Snijders C; Ader H; Heine RJ
    Diabet Med; 1997 Mar; 14(3):248-57. PubMed ID: 9088775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients.
    Bruttomesso D; Pianta A; Mari A; Valerio A; Marescotti MC; Avogaro A; Tiengo A; Del Prato S
    Diabetes; 1999 Jan; 48(1):99-105. PubMed ID: 9892228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.
    Feinglos MN; Thacker CH; English J; Bethel MA; Lane JD
    Diabetes Care; 1997 Oct; 20(10):1539-42. PubMed ID: 9314631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.
    Heinemann L; Heise T; Wahl LC; Trautmann ME; Ampudia J; Starke AA; Berger M
    Diabet Med; 1996 Jul; 13(7):625-9. PubMed ID: 8840095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.